Tecentriq for Locally Advanced or Metastatic Urothelial Carcinoma

News
Article

Tecentriq Product Image

Tecentriq (atezolizumab, Genetech)

Indications: Patients with locally advanced or metastatic urothelial carcinoma

  • Not eligble for cisplatin-containing chemotherapy & whose tumors express PD-L1

  • Not eligible for any platinum-containing chemotherapy regardless of PD-L1 status

  • Have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy

Dosage

  • Metastatic Urothelial Carcinoma or Previously Treated NSCLC
  • 1200 mg intravenously 60 mins x 3weeks

  • 1200 mg IV over 60 minutes, followed by bevacizumab, paclitaxel and carboplatin, on the same day every 3 weeks x4-6

Contraindications: none

Click here for more prescribing information

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.